Epidermal Growth Factor (EGF), also known as urogastrone, is an endogenous polypeptide growth factor primarily produced by various cells, including epithelial cells, fibroblasts, and macrophages. It belongs to the class of proteins known as growth factors and plays a crucial role in cell growth, proliferation, and differentiation. EGF is synthesized as a precursor protein and is cleaved to produce the active form. It is also available in synthetic forms for research and therapeutic purposes. Researchers have extensively studied EGF for its role in wound healing, tissue regeneration, and its potential implications in cancer biology. EGF is known to stimulate the proliferation of epidermal and epithelial cells, making it a significant focus in dermatological and oncological research. It has been investigated for its ability to enhance wound healing and its involvement in tumorigenesis, given its role in cell proliferation. The mechanism of action of EGF involves binding to the epidermal growth factor receptor (EGFR), a transmembrane receptor with intrinsic tyrosine kinase activity. Upon binding, EGFR undergoes dimerization and autophosphorylation, activating downstream signaling pathways such as the MAPK, PI3K/Akt, and JAK/STAT pathways, which lead to cellular responses including proliferation and survival. Pharmacokinetically, EGF has a short circulating half-life, typically around 10 minutes when administered intravenously. It is rapidly cleared from the circulation, primarily metabolized by the liver and kidneys. The bioavailability of EGF varies significantly depending on the route of administration, with poor oral bioavailability due to degradation in the gastrointestinal tract. Clinically, EGF is used in certain topical formulations to promote wound healing and skin regeneration. It is not widely approved for systemic use due to its rapid clearance and potential for promoting tumorigenesis. Regulatory approval varies by region, with some topical applications approved for use in specific conditions.